Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Operating Expenses (2020 - 2025)

Rani Therapeutics Holdings has reported Operating Expenses over the past 6 years, most recently at $10.0 million for Q4 2025.

  • Quarterly results put Operating Expenses at $10.0 million for Q4 2025, down 37.47% from a year ago — trailing twelve months through Dec 2025 was $39.9 million (down 26.5% YoY), and the annual figure for FY2025 was $39.9 million, down 26.5%.
  • Operating Expenses for Q4 2025 was $10.0 million at Rani Therapeutics Holdings, up from $7.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for RANI hit a ceiling of $27.8 million in Q3 2021 and a floor of $6.0 million in Q1 2021.
  • Median Operating Expenses over the past 5 years was $13.6 million (2022), compared with a mean of $13.9 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 846.54% in 2021 and later crashed 41.18% in 2022.
  • Rani Therapeutics Holdings' Operating Expenses stood at $13.4 million in 2021, then soared by 30.83% to $17.5 million in 2022, then dropped by 23.16% to $13.4 million in 2023, then rose by 19.0% to $16.0 million in 2024, then plummeted by 37.47% to $10.0 million in 2025.
  • The last three reported values for Operating Expenses were $10.0 million (Q4 2025), $7.3 million (Q3 2025), and $10.5 million (Q2 2025) per Business Quant data.